NTRK gene fusion overexpression – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:13 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png NTRK gene fusion overexpression – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion https://clinicaltrials.eu/trial/study-on-larotrectinib-for-treating-children-with-advanced-solid-tumors-with-ntrk-fusion/ Wed, 29 Apr 2026 14:25:54 +0000 https://clinicaltrials.eu/trial/study-on-larotrectinib-for-treating-children-with-advanced-solid-tumors-with-ntrk-fusion/ This clinical trial is focused on studying the effects of a medication called larotrectinib in children with certain types of tumors. These tumors are known as solid tumors that have a specific genetic change called NTRK fusion. The study aims to test the safety and effectiveness of larotrectinib in treating these tumors. Larotrectinib is taken by mouth, either as a capsule or an oral solution.

The purpose of the study is to understand how safe larotrectinib is for children and how well it works in shrinking or controlling the tumors. The study is divided into two phases. In the first phase, the focus is on determining the safety of the medication and identifying any side effects. In the second phase, the study looks at how well the tumors respond to the treatment, which means checking if the tumors get smaller or stop growing.

Participants in the study will receive larotrectinib and will be monitored by healthcare professionals to observe any changes in their condition. The study will help gather important information about the potential benefits and risks of using larotrectinib for treating tumors with NTRK fusion in children. This research is important for developing new treatments for these types of tumors and improving the care of children affected by them.

]]> Study on How Larotrectinib Works in Adults with Solid Tumors with NTRK Gene Fusion https://clinicaltrials.eu/trial/study-on-how-larotrectinib-works-in-adults-with-solid-tumors-with-ntrk-gene-fusion/ Wed, 29 Apr 2026 14:25:20 +0000 https://clinicaltrials.eu/trial/study-on-how-larotrectinib-works-in-adults-with-solid-tumors-with-ntrk-gene-fusion/ This clinical trial is focused on studying the effectiveness of a drug called Larotrectinib in treating adults with various types of solid cancers that have a specific genetic change known as NTRK fusion. Solid cancers are tumors that form in solid organs or tissues, such as the breast, lung, or colon, as opposed to blood cancers like leukemia. The genetic change, NTRK fusion, involves the joining of an NTRK gene with another gene, which can lead to cancer growth. The drug Larotrectinib is designed to target and inhibit the activity of these fused genes, potentially stopping or slowing the growth of the cancer.

The purpose of this study is to learn how well Larotrectinib works in treating these cancers. Participants in the study will receive Larotrectinib in the form of an oral solution or a hard capsule. The study will monitor the participants’ response to the treatment over a period of time, looking for signs of tumor shrinkage or stabilization. Some participants may receive a placebo, which is a substance with no active drug, to compare the effects of Larotrectinib against no treatment. The study aims to determine the overall response rate, which is the proportion of participants who experience a significant reduction in tumor size or complete disappearance of the tumor.

Throughout the study, participants will have regular check-ups and imaging tests, such as MRI or computed tomography (CT), to assess the size and progression of their tumors. The study will also evaluate the duration of response, which is how long the tumor remains reduced in size, and other outcomes like progression-free survival, which is the length of time during and after treatment that the cancer does not worsen. The safety of Larotrectinib will be closely monitored, with any side effects being recorded and analyzed. The study is expected to continue until October 2025.

]]>